COVID-19 vaccine it is developing with German partner BioNTech in late November, making it unlikely a vaccine will be available before U.S.
elections as President Donald Trump has promised.The regulatory filing for the vaccine could come as soon as safety data is available, possibly in the third week of November, Pfizer said, lifting the company’s shares and the broader U.S.
stock market.The timeline now allows for a possible U.S. authorization of a coronavirus vaccine this year, a key step in controlling the COVID-19 pandemic, which has killed more than a million people and ravaged the global economy.[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]The U.S.